Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 12/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | NPC1 | O15118 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.47 |
| ▸ | RELA | Q04206 | 3/20 | 0.47 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3661525 | 0.84 | SMN1; SMN2 (0.58) | SMN1; SMN2HPGDRAB9AALDH1A1NPC1 | |
| SCHEMBL4472873 | 0.83 | RAB9A (0.58) | SMN1; SMN2HPGDRAB9AALDH1A1NPC1 | |
| SCHEMBL4475058 | 0.82 | MEN1 (0.46) | SMN1; SMN2HPGDRAB9AALDH1A1NPC1 | |
| SCHEMBL4494427 | 0.82 | SMN1; SMN2 (0.44) | SMN1; SMN2HPGDRAB9AALDH1A1NPC1 | |
| SCHEMBL4474644 | 0.80 | NPY5R (0.44) | SMN1; SMN2HPGDRAB9AALDH1A1NPC1 | |
| SCHEMBL4494474 | 0.80 | ALDH1A1 (0.52) | SMN1; SMN2HPGDRAB9AALDH1A1NPC1 | |
| SCHEMBL5287237 | 0.80 | NPC1 (0.48) | SMN1; SMN2HPGDRAB9AALDH1A1NPC1 | |
| SCHEMBL23400674 | 0.79 | P2RY6 (0.43) | SMN1; SMN2HPGDRAB9AALDH1A1NPC1 | |
| SCHEMBL5287227 | 0.79 | P2RY6 (0.43) | SMN1; SMN2HPGDRAB9AALDH1A1NPC1 | |
| SCHEMBL2160020 | 0.78 | KDM4E (0.45) | SMN1; SMN2HPGDRAB9AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114031556-B | Synthetic method for preparing 5-amino-N-aryl-3-arylpyrazole compound by green one-pot method | 温州大学 | 2023-03-31 | — | — | CN | claimed |
| CN-114031556-B | Synthetic method for preparing 5-amino-N-aryl-3-arylpyrazole compound by green one-pot method | 温州大学 | 2023-03-31 | — | — | CN | disclosed |
| US-11312722-B2 | Hsp90 inhibitors and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| US-20200354373-A1 | HSP90 INHIBITORS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-11-12 | — | — | US | disclosed |
| EP-2078002-B1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8227605-B2 | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | SCHERING CORPORATION (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227605-B2 | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | SCHERING CORPORATION (US) | 2012-07-24 | — | — | US | disclosed |
| US-20100055090-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-03-04 | — | — | US | disclosed |
| US-20100055090-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-03-04 | — | — | US | disclosed |
| US-7485658-B2 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1641454-B1 | PYRAZOLO[3,4-B]PYRIDIN-6-ONES AS GSK-3 INHIBITORS | PFIZER PROD INC (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20080221187-A9 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008054701-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-05-08 | — | — | WO | disclosed |
| US-7300943-B2 | GSK-3 inhibitors | PFIZER INC. (US) | 2007-11-27 | — | — | US | disclosed |
| EP-1641454-A1 | PYRAZOLO[3,4-B]PYRIDIN-6-ONES AS GSK-3 INHIBITORS | Pfizer Products Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050026946-A1 | GSK-3 inhibitors | PFIZER INC | 2005-02-03 | — | — | US | disclosed |
| WO-2005000303-A1 | PYRAZOLO`3,4-B!PYRIDIN-6-ONES AS GSK-3 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100055090-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MAPK15, CDK15, MAP3K15 | SMN1; SMN2 3576/4885HPGD 3349/4885RAB9A 4517/4885 |
| US-20080221187-A9 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | KIT, TNNI3K, CHUK | SMN1; SMN2 2965/4885HPGD 756/4885RAB9A 977/4885 |
| US-20200354373-A1 | HSP90 INHIBITORS AND USES THEREOF | HSP90AB1, HSP90B1, HSP90AA1 | SMN1; SMN2 4707/4885HPGD 947/4885RAB9A 1480/4885 |
| US-20050026946-A1 | GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | SMN1; SMN2 2649/4885HPGD 2683/4885RAB9A 2757/4885 |
| US-11312722-B2 | Hsp90 inhibitors and uses thereof | HSP90AB1, HSP90B1, HSP90AA1 | SMN1; SMN2 4707/4885HPGD 947/4885RAB9A 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.